Insulet price target raised to $245 from $240 at Wells Fargo

Wells Fargo raised the firm’s price target on Insulet to $245 from $240 on Friday, while keeping an Overweight rating on the shares. The firm reported Q2 sales in line with the July pre-announcement and raised 2024 guidance. Early demand on O5/G7 is strong and a broader retail launch is expected to come in Q3. U.S. O5/L2 launch planned by year-end 2024. Outside-U.S. O5 adoption continues to be robust, Wells adds.